PolyPid (PYPD) Total Current Liabilities (2019 - 2026)
PolyPid (PYPD) posted Total Current Liabilities of $7.0 million for Q1 2026, down 8.93% sequentially from $7.7 million in Q4 2025, and down 43.1% YoY from $12.4 million in Q1 2025.
PolyPid (PYPD) Total Current Liabilities (2019 - 2026) Analysis & Trends
PolyPid has reported Total Current Liabilities for 8 years, with the latest figure at $7.0 million in Q1 2026.
- Quarterly Total Current Liabilities fell 43.1% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (down 43.1% YoY) and the FY2025 annual result came in at $7.7 million, down 38.97% from the prior year.
- Total Current Liabilities declined to $7.0 million in Q1 2026 per PYPD's latest filing, from $7.7 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $13.2 million in Q2 2025 and troughed at $5.5 million in Q2 2023.
- A 5-year average of $8.7 million and a median of $7.7 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 101.43% in 2022, then slumped 43.1% in 2026.
- Over 5 years, Total Current Liabilities stood at $8.6 million in 2022, then dropped by 14.81% to $7.3 million in 2023, then soared by 74.05% to $12.7 million in 2024, then slumped by 38.97% to $7.7 million in 2025, then dropped by 8.93% to $7.0 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $7.0 million, $7.7 million, and $7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 6.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.60 Mn |
| Mar 31, 2026 | 7.05 Mn |
| Dec 31, 2025 | 7.74 Mn |
| Sep 30, 2025 | 7.62 Mn |
| Jun 30, 2025 | 13.16 Mn |
| Mar 31, 2025 | 12.39 Mn |
| Dec 31, 2024 | 12.68 Mn |
| Sep 30, 2024 | 10.48 Mn |
| Jun 30, 2024 | 10.29 Mn |
| Mar 31, 2024 | 9.20 Mn |
| Dec 31, 2023 | 7.29 Mn |
| Sep 30, 2023 | 5.90 Mn |
| Jun 30, 2023 | 5.45 Mn |
| Mar 31, 2023 | 7.50 Mn |
| Dec 31, 2022 | 8.55 Mn |
| Sep 30, 2022 | 6.89 Mn |
| Jun 30, 2022 | 8.70 Mn |
| Mar 31, 2022 | 6.44 Mn |
| Dec 31, 2021 | 8.08 Mn |
| Sep 30, 2021 | 5.14 Mn |